Company Overview

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the treatment of highly resistant cancers. We have three core technologies, all of which are based on discoveries made at M.D. Anderson Cancer Center by Dr. Waldemar Priebe and his team. Our clinical stage drugs are Annamycin, a Next Generation Anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, or AML, and WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer and AML. We are also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as Metabolism/Glycosylation Inhibitors.

Our Next Generation Anthracycline, Annamycin, is unlike any currently approved anthracyclines, as it is designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin has preliminary clinical data suggesting its potential to become the first successful therapy suitable for the majority of relapsed or refractory AML patients and is currently in two Phase VII clinical trials.

WP1066 is one of several Immune/Transcription Modulators capable of stimulating immune response to tumors by inhibiting the errant activity of Regulatory T-Cells (TRegs) while also inhibiting key oncogenic transcription factors, including p-STAT3, c-Myc and HIF-1α. These transcription factors are widely sought targets that may also play a role in the inability of immune checkpoint inhibitors to affect more resistant tumors.

We are also developing new prodrugs to exploit the potential uses of inhibitors of glycolysis. Our lead Metabolism/Glycosylation inhibitor compound, WP1122, provides an opportunity to cut off the fuel supply of tumors by taking advantage of their overdependence on glucose as compared with healthy cells. New research also points to the potential for the glucose decoy (2-DG) within WP1122 to be capable of enhancing the usefulness of checkpoint inhibitors.

Management Team

Walter V. Klemp
Founder, President, Chairman, CEO, and Business Advisory Board Member

Donald Picker, PhD
Chief Scientific Officer

Robert Shepard, MD, FACP
Chief Medical Officer - Hematology

Sandra Silberman, MD, PhD
Chief Medical Officer - New Products

Jonathan P. Foster
Chief Financial Officer

Moleculin Biotech, Inc.
5300 Memorial Drive
Suite 950
Houston, TX 77007

Moleculin Announces Annamycin in Acute Myeloid Leukemia in Poland
Advances to 3rd Cohort
Jul 18 2019, 7:30 AM EDT

Moleculin Files for New Patents for Annamycin After Receiving FDA
Approval of Fast Track Designation
Jul 10 2019, 7:30 AM EDT

Moleculin Biotech, Inc. Reports Financial Results for the First Quarter
Ended March 31, 2019
May 14 2019, 7:30 AM EDT

Stock Overview

<table>
<thead>
<tr>
<th>Symbol</th>
<th>MBRX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exchange</td>
<td>Nasdaq</td>
</tr>
<tr>
<td>Market Cap</td>
<td>47.9m</td>
</tr>
<tr>
<td>Last Price</td>
<td>$1.06</td>
</tr>
<tr>
<td>52-Week</td>
<td>$0.777212 - $3.15</td>
</tr>
</tbody>
</table>

Investor Relations

Lytham Partners, LLC
Joe Dorame
Managing Partner
T: (602) 889-9700

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.